431 related articles for article (PubMed ID: 27999017)
21. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
[TBL] [Abstract][Full Text] [Related]
22. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
[TBL] [Abstract][Full Text] [Related]
23. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
[TBL] [Abstract][Full Text] [Related]
24. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
25. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
26. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
Negredo E; Estrada V; Domingo P; Gutiérrez MD; Mateo GM; Puig J; Bonjoch A; Ornelas A; Echeverría P; Estany C; Toro J; Clotet B
J Antimicrob Chemother; 2017 Mar; 72(3):844-849. PubMed ID: 27999056
[TBL] [Abstract][Full Text] [Related]
27. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.
Borghetti A; Baldin G; Ciccullo A; Gagliardini R; D'Avino A; Mondi A; Ciccarelli N; Lamonica S; Fanti I; Trecarichi E; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2016 Aug; 71(8):2359-61. PubMed ID: 27147306
[No Abstract] [Full Text] [Related]
28. HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen.
Fabrizio C; de Gennaro N; Volpe A; Scudeller L; Lagioia A; Falasca K; Ladisa N; Angarano G; Monno L; Saracino A
J Clin Virol; 2018 Dec; 109():45-49. PubMed ID: 30471517
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
Moreno S; Berenguer J
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
[TBL] [Abstract][Full Text] [Related]
30. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
31. Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.
Hawkins KL; Montague BT; Rowan SE; Beum R; McLees MP; Johnson S; Gardner EM
Antivir Ther; 2019; 24(7):513-519. PubMed ID: 31538963
[TBL] [Abstract][Full Text] [Related]
32. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.
Katlama C; Soulié C; Caby F; Denis A; Blanc C; Schneider L; Valantin MA; Tubiana R; Kirstetter M; Valdenassi E; Nguyen T; Peytavin G; Calvez V; Marcelin AG
J Antimicrob Chemother; 2016 Sep; 71(9):2646-50. PubMed ID: 27287235
[TBL] [Abstract][Full Text] [Related]
33. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
34. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.
Salou M; Dagnra AY; Butel C; Vidal N; Serrano L; Takassi E; Konou AA; Houndenou S; Dapam N; Singo-Tokofaï A; Pitche P; Atakouma Y; Prince-David M; Delaporte E; Peeters M
J Int AIDS Soc; 2016; 19(1):20683. PubMed ID: 27125320
[TBL] [Abstract][Full Text] [Related]
35. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
Cavalcanti Jde S; Ferreira JL; Guimarães PM; Vidal JE; Brigido LF
J Antimicrob Chemother; 2015 Mar; 70(3):926-9. PubMed ID: 25386009
[TBL] [Abstract][Full Text] [Related]
36. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study.
Devendra A; Kohler M; Letsika M; Khooa H; Motaboli L; Lerotholi M; Tschumi N; Labhardt ND; Brown JA
AIDS; 2024 Jun; 38(7):1013-1023. PubMed ID: 38381717
[TBL] [Abstract][Full Text] [Related]
37. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
39. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
Nyaku AN; Zheng L; Gulick RM; Olefsky M; Berzins B; Wallis CL; Godfrey C; Sax PE; Acosta EP; Haas DW; Smith KY; Sha BE; Van Dam CN; Taiwo BO;
J Antimicrob Chemother; 2019 May; 74(5):1376-1380. PubMed ID: 30668695
[TBL] [Abstract][Full Text] [Related]
40. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.
Rojas J; Blanco JL; Marcos MA; Lonca M; Tricas A; Moreno L; Gonzalez-Cordon A; Torres B; Mallolas J; Garcia F; Gatell JM; Martinez E
J Antimicrob Chemother; 2016 Jul; 71(7):1975-81. PubMed ID: 27021341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
